GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-09-30

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with thalassemia intermedia, congenital dyserythropoietic anemia type I , and sideroblastic anemia were found to express very high levels of serum GDF15, and this contributed to the inappropriate suppression of hepcidin with subsequent secondary iron overload.The aim of our present study is to asses the levels of GDF15 and hepcidin in patients with Sickle cell disease and hereditary spherocytosis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The identification of the ferroportin/hepcidin axis has allowed the effect of erythroid activity on iron balance to be studied and has created the basis for better defining the erythroid regulators.

In iron-loading anemias, ineffective erythropoiesis suppresses hepcidin production, which result in dysregulating iron homeostasis. Miller and co-workers showed that release of cytokines like growth differentiation factor 15 (GDF15) during the process of ineffective erythropoiesis inhibits hepcidin production, thus defining a molecular link between ineffective erythropoiesis, suppression of hepcidin production and parenchymal iron loading.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients With Thalassemia Intermedia, Congenital Dyserythropoietic Anemia Type I

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sickle cell disease

No interventions assigned to this group

hereditary spherocytosis.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* non

Exclusion Criteria

* non

Minimum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

hematology department on Wolfsson Medical Center

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GHOTI HOSSAM, doctor

Role: PRINCIPAL_INVESTIGATOR

HEMATOLOGY DEPARTMENT ON WOLFSSON MEDICAL CENTER

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ghoti Hossam, doctor

Role: CONTACT

[email protected]

035028110

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GDF-15CTIL

Identifier Type: -

Identifier Source: org_study_id